Insulet Bolsters its Executive Management With Appointment of Two VPs

Insulet Corporation, a developer of tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), has appointed Dr. Trang Ly as its vice president and medical director, effective Sept 12. In addition, Brittany Bradrick has been appointed vice president of strategy and corporate development, a newly-created position, effective Sept. 2.
 
Ly is an expert in artificial pancreas research and development and brings particular expertise in advancing algorithms for automated insulin delivery. She joins Insulet from Stanford University, where she served as clinical assistant professor in the Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes.
 
As vice president of strategy and corporate development, Bradrick will be responsible for advancing key strategic partnerships, identifying external growth opportunities and leading Insulet’s strategic planning initiatives. She is an accomplished strategy and finance professional with significant life science experience in both corporations and investment banking. She joins Insulet from Abbott Diabetes Care, where she served as director of business development and alliance management.
 
“We are very pleased to welcome Trang and Brittany to our executive team,” said Patrick Sullivan, president and CEO. “Trang is one of the nation’s leading experts in artificial pancreas research and development with years of clinical experience in endocrinology and diabetes in the United States and Australia. Her expertise will be a significant asset as we continue to advance our artificial pancreas program and broaden our product development agenda. Brittany brings deep industry knowledge and an exceptional skillset to our leadership team. She will partner with our management team to help Insulet advance our strategic roadmap and maximize the full potential of our external partnerships.”
 
Ly most recently has held positions at both Stanford University and University of Western Australia, as clinical assistant professor and research assistant professor, respectively. Prior to her time at Stanford, Ly was a consultant pediatric endocrinologist in the Department of Endocrinology and Diabetes at Princess Margaret Hospital for Children in Perth, Australia. She has a bachelor of medicine and surgery degree, a diploma of child health and a Ph.D. in pediatrics and pediatrics endocrinology from the University of Western Australia. She is also a fellow of the Royal Australasian College of Physicians with specialist qualifications in pediatrics endocrinology.
 
Bradrick joins Insulet from Abbott Diabetes Care, where she was director, business development and alliance management, responsible for leading the division’s global business development efforts, including strategy, acquisitions, dispositions, global partnerships and licensing of intellectual property and technology. Prior to Abbott, Bradrick advised life science companies for more than 10 years as an investment banker with Piper Jaffray, Credit Suisse and JP Morgan. She earned a bachelor of science degree in business administration from the University of Missouri and an M.B.A. from the Johnson Graduate School of Management at Cornell University.
 
Through its Omnipod Insulin Management System, Insulet Corporation seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet’s Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Mass.